{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-006697","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.752512+00:00","generated_at":"2026-06-18T09:32:27.095331+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aquestive Q4 revenues down 4% YoY to $10.7M; guides FY2023 rev $37-41M; AQST-109 pivotal study on track for Q3","bullets":["Q4 2022 total revenues $10.7M vs $11.1M YoY; net loss $12.4M ($0.23/sh) vs $28.9M ($0.72/sh) in Q4 2021.","Full year 2022 total revenues $47.7M, down 6% YoY; net loss $54.4M ($1.12/sh) vs $70.5M ($1.85/sh).","FY2023 guidance: total revenue $37-41M; non-GAAP adjusted EBITDA loss $31-36M.","AQST-109 pivotal study protocol to be submitted to FDA in Q2 2023; study start expected Q3 2023.","Patent litigation settled with BDSI for $8.5M payment to Aquestive; Indivior agreement extended to 2026 with $11.5M one-time payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-006697","json":"https://secwatch.observer/filing/0001628280-23-006697.json","markdown":"https://secwatch.observer/filing/0001628280-23-006697.md","text":"https://secwatch.observer/filing/0001628280-23-006697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023006697/0001628280-23-006697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023006697/aqst-20230307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:32:27.095331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d3e97481efe0de0fde61ddb83355890cdddf3730","claim":"Aquestive Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the quarter and fiscal year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023006697/0001628280-23-006697-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}